Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: From in vitro data to clinical study design

Xenobiotica

Volumn 43, Issue 6, 2013, Pages 498-508

  Polli, Joseph W ^a   Hussey, Elizabeth ^b   Bush, Mark ^b   Generaux, Grant ^a   Smith, Glenn ^a   Collins, David ^b   McMullen, Susan ^b   Turner, Nancy ^b   Nunez, Derek J ^a  

^a GLAXOSMITHKLINE   (United States)

^b CVM MDC Clinical Pharmacology and Discovery ^*  (Japan)

Author keywords

BCRP; Cytochrome P450; Diabetes; Dyslipidemia; OATP; P glycoprotein; Pharmacogenetics; Transporters

Indexed keywords

[1 (3 ISOPROPYL 1,2,4 OXADIAZOL 5 YL)PIPERIDIN 4 YL]METHYL METHANESULFONATE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ELACRIDAR; GSK 1292263; MESYLIC ACID DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; OCTAMER TRANSCRIPTION FACTOR 2; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANIMALS; CYTOCHROME P-450 CYP3A; DEMOGRAPHY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MESYLATES; MIDDLE AGED; OXADIAZOLES; PIPERIDINES; PYRIMIDINES; PYRROLES; REFERENCE STANDARDS; SIMVASTATIN; SULFONAMIDES; TROLEANDOMYCIN; YOUNG ADULT;

EID: 84872715452     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.739719     Document Type: Article

References (28)

1. Abd TT, Jacobson TA. (2011). Statin-induced myopathy: A review and update. Expert Opin Drug Saf 10:373-387
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
3. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J. (2008). A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149:2038-2047 (Pubitemid 351574507)
4. Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. (2007). Musculoskeletal adverse drug reactions: A review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2:47-63 (Pubitemid 46729093)
5. Crestor (rosuvastatin calcium) Label. FDA Drug Label. (2012) http://www.accessdat a . f da. gov / d rugsat f da-doc s /label/2012/ 021366Orig1s024Lbl.pdf
6. Florentin M, Elisaf MS. (2012). Simvastatin interactions with other drugs. Expert Opin Drug Saf 11:439-444
7. Food and Drug Administration. (2012) Guidance for Industry Drug Interaction Studies -Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
8. Generaux GT, Bonomo FM, Johnson M, Doan KM. (2011). Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:639-651
9. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236
10. Hauschke D, Steinijans VW, Diletti E. (1990). A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:72-78 (Pubitemid 20098974)
11. Jones RM, Leonard JN, Buzard DJ, Lehmann J. (2009). GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 19:1339-1359
12. Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Sarich TC, Stein PP. (2012). Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebocontrolled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14:709-716
13. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. (2008). ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457-461
14. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. (2009a). Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624
15. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009b). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203
16. Levien TL, Baker DE. (2009). New Drugs in Development for the Treatment of Diabetes. Diabetes Spectrum 22, 92-106
17. Mathers CD, Boerma T, Ma Fat D. (2009). Global and regional causes of death. Br Med Bull 92:7-32
18. Neuvonen PJ, Backman JT, Niemi M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47:463-474 (Pubitemid 351861958)
19. Niemi M. (2010). Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130-133
20. Nunez DJ, Bush MA, Collins DA, McMullen SL, Apseloff G, Cosino L, Morrow L, Feldman PL. (2012). Effects on Lipids of GSK1292263, a GPR119 Agonist, in Type 2 Diabetics. Diabetes 61, 1084-P.
21. Nunez DJ, Bush MA, Collins DA, McMullen SL, Feldman PL, Jackson TD, Ross SA. (2011). Evaluation of GSK1292263, a Novel GPR119 Agonist, in Type 2 Diabetes Mellitus (T2DM): Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses. Diabetes 60, 996-P.
22. Nunez DJ, Lewis EW, Swan S, Bush MA, Cannon C, McMullen SL, Collins DA, Feldman PL. (2010). A Study in Healthy Volunteers To Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses of GSK1292263, a Novel GPR119 Agonist. Diabetes 58, 80-OR.
23. Ohishi T, Yoshida S. (2012). The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 21:321-328
24. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733 (Pubitemid 350114817)
25. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879 (Pubitemid 44772805)
26. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl) ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695-701 (Pubitemid 351468376)
27. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34:786-792
28. Zocor (simvastatin) Drug Label. FDA Drug Label. (2012). http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/019766s085lbl.pdf.